| scholarly article | Q13442814 |
| P50 | author | Robert K Hills | Q37830377 |
| Christopher Allen | Q51119388 | ||
| Adam J Mead | Q57032592 | ||
| Rosemary Gale | Q59828924 | ||
| David C Linch | Q89467453 | ||
| P2093 | author name string | Alan K Burnett | |
| Claire Green | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| patient | Q181600 | ||
| acute myeloid leukemia | Q264118 | ||
| P304 | page(s) | 2776-84 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia | |
| P478 | volume | 111 |
| Q28072539 | 'Acute myeloid leukemia: a comprehensive review and 2016 update' |
| Q33889001 | A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia |
| Q36304815 | A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML. |
| Q90425435 | A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1 |
| Q42192063 | A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response |
| Q64125995 | A phase 2 study incorporating sorafenib into the chemotherapy for older adults with -mutated acute myeloid leukemia: CALGB 11001 |
| Q46931556 | A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. |
| Q41973517 | A potential therapeutic target for FLT3-ITD AML: PIM1 kinase |
| Q39166725 | A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. |
| Q37373040 | AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) |
| Q44113808 | ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification |
| Q39905532 | ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia |
| Q37798016 | Acute Myeloid Leukemia Diagnosis in the 21st Century |
| Q26766719 | Acute Myeloid Leukemia: A Concise Review |
| Q36085513 | Acute monocytic leukaemia with t(11; 12) (p15; q13) chromosomal changes: A case report and literature review |
| Q39400164 | Acute myeloid leukaemia genomics. |
| Q34327218 | Acute myeloid leukaemia in adults |
| Q36914091 | Acute myeloid leukaemia: optimal management and recent developments |
| Q91768661 | Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin |
| Q36849666 | Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification |
| Q38027047 | Acute myeloid leukemia with normal cytogenetics |
| Q27851694 | Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management |
| Q34665691 | Acute myeloid leukemia: 2014 update on risk-stratification and management |
| Q36508630 | Advances in paediatric cancer treatment |
| Q30277009 | Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia |
| Q48568744 | Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
| Q26996818 | Allogeneic stem cell transplantation in first complete remission |
| Q37514846 | Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. |
| Q34197535 | An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia |
| Q54325426 | Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3-ITD to detect patients with prognostically adverse AML. |
| Q34754867 | Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype |
| Q35753087 | Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis. |
| Q39645483 | Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype |
| Q51287950 | Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia. |
| Q48271873 | BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype. |
| Q36727867 | Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups |
| Q39098284 | Biological and clinical consequences of NPM1 mutations in AML. |
| Q27612411 | CIViC database |
| Q98725872 | Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells |
| Q54392727 | Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. |
| Q26797245 | Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis |
| Q60050025 | Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in mutated acute myeloid leukemia |
| Q53397583 | Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia. |
| Q58558233 | Clinical use of FLT3 inhibitors in acute myeloid leukemia |
| Q42609684 | Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. |
| Q56968572 | Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia |
| Q39601810 | Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio |
| Q36390379 | Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. |
| Q90010398 | Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing |
| Q43797937 | Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse |
| Q33702150 | Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML |
| Q57058970 | Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care |
| Q35669870 | Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. |
| Q47965783 | Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase |
| Q37158516 | Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture |
| Q37624593 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel |
| Q33741208 | Discovery of cancer common and specific driver gene sets |
| Q34295164 | Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data |
| Q39144248 | Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation |
| Q48328410 | Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant |
| Q37252482 | Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia |
| Q35800831 | Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice |
| Q39138902 | Establishment of xenotransplantation model of human CN-AML with FLT3-ITD (mut) /NPM1 (-) in NOD/SCID mice |
| Q89081092 | Evaluating measurable residual disease in acute myeloid leukemia |
| Q84615573 | FLT3 Mutations at Diagnosis and Relapse in Acute Myeloid Leukemia: Cytogenetic and Pathologic Correlations, Including Cuplike Blast Morphology |
| Q39513601 | FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations |
| Q38026453 | FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia |
| Q38101284 | FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance |
| Q37810061 | FLT3 inhibitors in acute myeloid leukemia |
| Q36012998 | FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group |
| Q27028163 | FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? |
| Q28289859 | FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations |
| Q54243631 | FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia. |
| Q39282600 | FLT3-ITD and its current role in acute myeloid leukaemia |
| Q36982190 | FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors |
| Q49181559 | FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics |
| Q37842585 | FMS-like tyrosine kinase 3 inhibitors: a patent review |
| Q42349214 | FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others |
| Q92023436 | Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia |
| Q82668142 | Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML |
| Q27851545 | Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study |
| Q34709391 | Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner |
| Q38767583 | Frontline treatment of acute myeloid leukemia in adults |
| Q33737486 | Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). |
| Q34595162 | Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status |
| Q91520849 | GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations |
| Q50482088 | GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. |
| Q34647741 | Gene mutations and molecularly targeted therapies in acute myeloid leukemia. |
| Q33415379 | Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia |
| Q38044773 | Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized? |
| Q54440164 | Genetic mutations in patients with acute myeloid leukemia and leukostasis. |
| Q33555627 | Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia |
| Q36917869 | Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse |
| Q50137311 | Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia |
| Q44695820 | Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours |
| Q42974502 | High DNA-methyltransferase 3B expression predicts poor outcome in acute myeloid leukemia, especially among patients with co-occurring NPM1 and FLT3 mutations |
| Q41036515 | High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial |
| Q64054053 | High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation |
| Q88890106 | How I treat older patients with acute myeloid leukemia |
| Q93023707 | Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis |
| Q31086279 | ITD assembler: an algorithm for internal tandem duplication discovery from short-read sequencing data |
| Q93059414 | Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia |
| Q36678141 | Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study |
| Q38694866 | Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. |
| Q54387022 | Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations. |
| Q60922682 | Impact of -ITD length on prognosis of acute myeloid leukemia |
| Q39140034 | Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype |
| Q90911358 | Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation |
| Q36823385 | Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo |
| Q91883004 | Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia |
| Q49668289 | Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report |
| Q34285896 | Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia |
| Q94521079 | Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia |
| Q38659416 | Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing. |
| Q41051992 | Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study |
| Q54653299 | Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia. |
| Q45891572 | Incidence of internal tandem duplications and D835 mutations of FLT3 gene in chronic myeloid leukemia patients from Southern India |
| Q45132395 | Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia |
| Q54990383 | Influence of IDH on FLT3-ITD status in newly diagnosed AML. |
| Q85849530 | Influence of ethnicity and improved outcome of acute myeloid leukaemia: two decades of follow-up of Israeli patient cohort |
| Q38989349 | Inhibition of FLT3 in AML: a focus on sorafenib |
| Q26748915 | Integrating mutation variant allele frequency into clinical practice in myeloid malignancies |
| Q37577934 | Investigational drugs targeting FLT3 for leukemia |
| Q38272140 | Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review |
| Q43188148 | Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability |
| Q37810104 | Lestaurtinib: a multi-targeted FLT3 inhibitor |
| Q54582393 | Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia. |
| Q33722630 | Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction |
| Q33829079 | Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients |
| Q36028489 | Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia |
| Q35525611 | Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice |
| Q35148420 | Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networ |
| Q34409299 | Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort |
| Q92512942 | MRD in AML: The Role of New Techniques |
| Q41509184 | Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia |
| Q94225748 | Managing the Continuum of Myeloid Malignancies |
| Q46576832 | Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. |
| Q24612217 | Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia |
| Q41856711 | Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia |
| Q47877035 | Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia |
| Q42376734 | Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis |
| Q58607135 | Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives |
| Q26799606 | Molecular Genetic Markers in Acute Myeloid Leukemia |
| Q92611548 | Molecular MRD status and outcome after transplantation in NPM1-mutated AML |
| Q45024752 | Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia |
| Q39116878 | Molecular landscape in acute myeloid leukemia: where do we stand in 2016 |
| Q38026007 | Molecular markers in acute myeloid leukaemia |
| Q38062865 | Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations |
| Q36983304 | Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia |
| Q45176487 | Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients |
| Q37316165 | Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features |
| Q42360131 | Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator? |
| Q39968471 | Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease |
| Q34044024 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr |
| Q50054236 | NPM1 Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction |
| Q51069547 | NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. |
| Q37599556 | NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease |
| Q34318490 | NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report |
| Q89014470 | New drugs in AML: uses and abuses |
| Q33886530 | Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation. |
| Q36144842 | Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia |
| Q28075654 | Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia |
| Q28069889 | Novel therapeutic options in Acute Myeloid Leukemia |
| Q38096798 | Novel therapies for children with acute myeloid leukaemia. |
| Q43160467 | Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies |
| Q34755985 | Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. |
| Q92503784 | Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia |
| Q33774504 | Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis |
| Q89896286 | Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML |
| Q33913329 | Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia |
| Q34095013 | Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia |
| Q33427443 | Possible involvement of RasGRP4 in leukemogenesis |
| Q92485655 | Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports |
| Q37270982 | Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia |
| Q41846388 | Prognostic Impact of Nucleophosmin 1 (NPM1) Gene Mutations in Egyptian Acute Myeloid Leukemia Patients |
| Q38183943 | Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. |
| Q27851642 | Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia |
| Q54489645 | Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia. |
| Q39631733 | Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype |
| Q57795857 | Prognostic impact of low allelic ratio ITD and mutation in acute myeloid leukemia |
| Q38289289 | Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. |
| Q39450821 | Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia |
| Q37954583 | Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics |
| Q58615883 | Prognostic models turn the Heat(IT)up on FLT3ITD-mutated AML |
| Q27853004 | Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. |
| Q41847123 | Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis |
| Q92488799 | Prognostic significance of PAK family kinases in acute myeloid leukemia |
| Q54307737 | Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia. |
| Q50420459 | Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. |
| Q34316768 | Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia |
| Q36457184 | Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia |
| Q92243267 | Prognostic significance of the PANK family expression in acute myeloid leukemia |
| Q34285937 | Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia |
| Q27024006 | Progress in acute myeloid leukemia |
| Q36022521 | Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length |
| Q54977319 | Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. |
| Q40329715 | RUNX1 cooperates with FLT3-ITD to induce leukemia. |
| Q36940606 | Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature |
| Q42149211 | Recent developments in management of older patients with acute myeloid leukemia |
| Q46122144 | Refining the prognostic importance of the diversity of FLT3 internal tandem duplications |
| Q38155455 | Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments |
| Q36544560 | Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients |
| Q94595584 | Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission |
| Q48250287 | Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. |
| Q33798909 | Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD |
| Q35028968 | Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. |
| Q43649404 | Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information |
| Q39841048 | Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia |
| Q91920608 | Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia |
| Q39105964 | Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML. |
| Q24338964 | Structural and functional alterations of FLT3 in acute myeloid leukemia |
| Q36657987 | Structural and numerical variation of FLT3/ITD in pediatric AML. |
| Q50629545 | TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. |
| Q35750567 | Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions |
| Q92708325 | Targeted variant detection using unaligned RNA-Seq reads |
| Q27851657 | Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. |
| Q104495182 | Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy |
| Q37662175 | Targeting prohibitins induces apoptosis in acute myeloid leukemia cells. |
| Q42587106 | The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia |
| Q90183794 | The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation |
| Q92757496 | The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia |
| Q28266484 | The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research |
| Q64075549 | The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients |
| Q37927089 | The clinical development of FLT3 inhibitors in acute myeloid leukemia |
| Q37655886 | The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia |
| Q38132064 | The evolving landscape in the therapy of acute myeloid leukemia |
| Q38216649 | The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond |
| Q48255430 | The importance of FLT3 mutational analysis in acute myeloid leukemia. |
| Q50893694 | The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. |
| Q38711002 | The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia |
| Q92253982 | The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia |
| Q39302268 | The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia |
| Q57461728 | The pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult AML |
| Q90592722 | The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting |
| Q87366126 | The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial |
| Q39363419 | The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. |
| Q37738548 | The role of molecular tests in acute myelogenous leukemia treatment decisions |
| Q38144189 | The role of quizartinib in the treatment of acute myeloid leukemia |
| Q94527686 | The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia |
| Q38198569 | The use of molecular genetics to refine prognosis in acute myeloid leukemia |
| Q36866323 | The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia |
| Q51818965 | Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. |
| Q38419355 | Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AM |
| Q38197075 | Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation |
| Q27851636 | Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients |
| Q33767026 | Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia |
| Q48272424 | Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. |
| Q41894404 | Update on optimal management of acute myeloid leukemia |
| Q26784052 | Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics |
| Q42979880 | Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect |
| Q90304391 | Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes |
| Q38182335 | Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? |
| Q86954339 | [Acute myeloid leukemia] |
| Q89021657 | [Advances of therapeutic strategies in hematological malignancies] |
Search more.